How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,138 results for

Hyperparathyroidism

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hyperparathyroidism (primary): diagnosis, assessment and initial management

Hyperparathyroidism (primary): diagnosis, assessment and initial management Hyperpar Hyperparath athyroidism (primary): yroidism (primary): diagnosis, assessment and initial diagnosis, assessment and initial management management NICE guideline Published: 23 May 2019 www.nice.org.uk/guidance/ng132 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132) © NICE 2019. All rights reserved. Subject to Notice of rights (https

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Primary hyperparathyroidism

Primary hyperparathyroidism Primary hyperparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Primary hyperparathyroidism Last reviewed: February 2019 Last updated: November 2018 Summary Diagnosis is confirmed biochemically with synchronous elevation of serum calcium and inappropriate elevation of parathyroid hormone (PTH). In 2017, normocalcaemic primary hyperparathyroidism (PHPT) was recognised (...) , but examination of the neck is essential to look for a hard, dense mass, suggestive of parathyroid carcinoma. Parathyroidectomy is the only definitive cure. Monitoring is an option for patients who have mild hypercalcaemia without surgical indications, which include lack of ensured follow-up, renal stones, impaired renal function, or osteoporosis. Definition Primary hyperparathyroidism (PHPT) is an endocrine disorder in which autonomous overproduction of parathyroid hormone (PTH) results in derangement

2018 BMJ Best Practice

6. Primary hyperparathyroidism

Primary hyperparathyroidism Primary hyperparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Primary hyperparathyroidism Last reviewed: February 2019 Last updated: November 2018 Summary Diagnosis is confirmed biochemically with synchronous elevation of serum calcium and inappropriate elevation of parathyroid hormone (PTH). In 2017, normocalcaemic primary hyperparathyroidism (PHPT) was recognised (...) , but examination of the neck is essential to look for a hard, dense mass, suggestive of parathyroid carcinoma. Parathyroidectomy is the only definitive cure. Monitoring is an option for patients who have mild hypercalcaemia without surgical indications, which include lack of ensured follow-up, renal stones, impaired renal function, or osteoporosis. Definition Primary hyperparathyroidism (PHPT) is an endocrine disorder in which autonomous overproduction of parathyroid hormone (PTH) results in derangement

2018 BMJ Best Practice

7. Secondary hyperparathyroidism

Secondary hyperparathyroidism Secondary hyperparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Secondary hyperparathyroidism Last reviewed: February 2019 Last updated: May 2018 Summary Parathyroid hormone (PTH) functions to maintain calcium homeostasis by acting on the renal tubules, on calcium stores in the skeletal system, and indirectly on the gastrointestinal (GI) tract through activation of vitamin (...) D and enteral absorption. Hypocalcaemia will elevate PTH levels and can serve as a cause of secondary hyperparathyroidism. Classically, this condition is caused by chronic kidney disease, intestinal malabsorption, or chronic inadequate sunlight exposure, which gives rise to characteristic alterations in vitamin D, phosphorus, and calcium. Inadequate vitamin D stores are common among older patients, particularly those who always use sunblock or are housebound, institutionalised, or hospitalised

2018 BMJ Best Practice

8. [Etelcalcetide (secondary hyperparathyroidism)]

[Etelcalcetide (secondary hyperparathyroidism)] Etelcalcetid (sekundärer hyperparathyreoidismus): addendum zum auftrag A17-25; addendum; auftrag A17-5 [Etelcalcetide (secondary hyperparathyroidism)] Etelcalcetid (sekundärer hyperparathyreoidismus): addendum zum auftrag A17-25; addendum; auftrag A17-5 [Etelcalcetide (secondary hyperparathyroidism)] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Etelcalcetid (sekundärer hyperparathyreoidismus): addendum zum auftrag A17-25; addendum; auftrag A17-5. [Etelcalcetide (secondary hyperparathyroidism)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 557. 2017 Final publication URL Indexing Status Subject

2018 Health Technology Assessment (HTA) Database.

9. [Etelcalcetide (secondary hyperparathyroidism) - benefit assessment according to õ35a Social Code Book V]

[Etelcalcetide (secondary hyperparathyroidism) - benefit assessment according to õ35a Social Code Book V] Etelcalcetid (sekundärer Hyperparathyreoidismus): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-25 [Etelcalcetide (secondary hyperparathyroidism) - benefit assessment according to §35a Social Code Book V] Etelcalcetid (sekundärer Hyperparathyreoidismus): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-25 [Etelcalcetide (secondary hyperparathyroidism (...) A17-25. [Etelcalcetide (secondary hyperparathyroidism) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 535. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone Language Published German Country of organisation Germany English summary There is no English language summary available. Address

2017 Health Technology Assessment (HTA) Database.

10. Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. (PubMed)

Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. Evaluation of bone is of great importance in chronic kidney disease patients, as these patients are at an increased risk for fractures. We treated a hemodialysis patient suffering from hyperparathyroid bone disease with cinacalcet hydrochloride and concurrent administration of maxacalcitol (...) and alfacalcidol for a year. Hyperparathyroid bone disease is characterized by cortical thinning, increased cortical porosity, reduced trabecular bone volume, and increased hypomineralized matrix volume, and there is little information to date about the effects of treatment with cinacalcet hydrochloride on the bone fragility in patients with hyperparathyroid bone disease. In the present study, histological and backscattered electron microscopic evaluation of this combination treatment revealed an excellent

2018 Osteoporosis International

11. Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome (PubMed)

Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome Primary hyperparathyroidism (PHPT) is a relatively rare disorder among children, adolescents and young adults. Its development at an early age is suspicious for hereditary causes, though the need for routine genetic testing remains controversial.To identify and describe hereditary forms of PHPT in patients with manifestation of the disease under 40 years of age.We enrolled 65

Full Text available with Trip Pro

2017 Endocrine connections

12. Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism (PubMed)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism 29988982 2019 02 26 2468-0249 3 4 2018 Jul Kidney international reports Kidney Int Rep Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism. 1010-1014 10.1016/j.ekir.2018.04.003 Sethi Sidharth Kumar SK Kidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India. Bansal Shyam Bihari SB Kidney Institute, Medanta, The Medicity, Gurgaon, Haryana

Full Text available with Trip Pro

2018 Kidney international reports

13. Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report (PubMed)

Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report Primary amyloidosis (PA) is a protein deposition disorder that presents with localized or multisystemic disease. The incidence is low in the general public, ranging from three to eight cases per million, and with nonspecific presenting symptoms typically occurring later in life. Due to late presentation, substantial and irreversible damage has usually already occurred (...) by the time of the diagnosis. However, if inadvertent diagnosis occurs before irreversible damage has taken place, as it did in the following case, some patients may benefit from the disease-arresting treatment. A 70-year-old female with a history of obstructive sleep apnea, hypertension, and arthritis presented with worsening dysphagia and biochemically confirmed primary hyperparathyroidism (PHPT). Further workup demonstrated multinodular goiter with compressive symptoms and substernal extension

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

14. Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. (PubMed)

Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. Avascular osteonecrosis (AVN) is a bone complication that indicates poor functional prognosis. Modern immunosuppressive and steroid-sparing drugs have significantly lowered the occurrence of AVN after kidney transplantation (KT). However, recent data on its incidence rates and risk factors are lacking. Using a large, recent cohort, we sought (...) -transplant diabetes or hyperparathyroidism at transplantation, developing acute rejection, and receiving higher cumulative corticosteroid doses were associated with AVN occurrence. Multivariate analysis revealed that BMI ≥ 26 kg/m2 and higher cumulative corticosteroid doses were predictive of AVN. In conclusion, overweight/obesity is a strong risk factor for AVN. Despite a low maintenance dose, the use of corticosteroids-mostly for treatment of acute rejection-remains an independent risk factor.

Full Text available with Trip Pro

2019 PLoS ONE

15. Calcifediol (Rayaldee) - for the treatment of secondary hyperparathyroidism

Calcifediol (Rayaldee) - for the treatment of secondary hyperparathyroidism Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2019 Health Canada - Drug and Health Product Register

16. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. (PubMed)

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronic kidney disease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first published

Full Text available with Trip Pro

2014 Cochrane

17. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. (PubMed)

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. Patients with chronic kidney disease have impaired vitamin D activation and elevated cardiovascular risk. Observational studies in patients treated with hemodialysis showed that the use of active vitamin D sterols was associated with lower risk of all-cause mortality, regardless of parathyroid hormone levels.To determine (...) whether vitamin D receptor activators reduce cardiovascular events and mortality in patients without secondary hyperparathyroidism undergoing hemodialysis.Randomized, open-label, blinded end point multicenter study of 1289 patients in 207 dialysis centers in Japan. The study included 976 patients receiving maintenance hemodialysis with serum intact parathyroid hormone levels less than or equal to 180 pg/mL. The first and last participants were enrolled on August 18, 2008, and January 26, 2011

2018 JAMA

18. Etelcalcetide for treating secondary hyperparathyroidism

Etelcalcetide for treating secondary hyperparathyroidism Etelcalcetide for treating secondary Etelcalcetide for treating secondary h hyperpar yperparath athyroidism yroidism T echnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Etelcalcetide for treating secondary hyperparathyroidism (TA448) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

19. Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25

Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25 1 Translation of addendum A17-53 Etelcalcetid (sekundärer Hyperparathyreoidismus) – Addendum zum Auftrag A17-25 (Version 1.0; Status: 27 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 October 2017 1.0 Commission: A17-53 Version: Status: IQWiG Reports (...) – Commission No. A17-53 Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 1 Addendum A17-53 Version 1.0 Etelcalcetide – Addendum to Commission A17-25 27 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 Commissioning agency: Federal Joint Committee Commission awarded on: 9 October 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism (PubMed)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism The pharmacokinetics, pharmacodynamics, and safety and tolerability profile of etelcalcetide (ONO-5163/AMG 416), a novel, i.v., long-acting calcium-sensing receptor agonist, were studied in Japanese hemodialysis patients with secondary hyperparathyroidism.This multicenter, randomized, double-blind, placebo-controlled, parallel-group study consisted of a single

Full Text available with Trip Pro

2017 Kidney international reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>